立体定向体部放疗对比常规分割放疗治疗前列腺癌的急性毒性:PACE-B 试验
PACE-B 是一项国际、开放标签、随机、非劣效性 3 期试验,纳入 874 例低危至中危局限性前列腺癌患者,比较常规分割或中度大分割放疗与 5 次立体定向体部放疗(SBRT)的急性毒性。结果显示,SBRT 组 12 周内 RTOG 2 级及以上胃肠和泌尿生殖系统急性毒性均未显著增加,未发生治疗相关死亡。
要点
- SBRT 大幅缩短疗程至 1-2 周,未增加急性胃肠或泌尿生殖毒性,无治疗相关死亡。
核心结论
- 对于低危至中危局限性前列腺癌,5 次 SBRT 相比常规分割或中度大分割放疗未增加 12 周内 2 级及以上急性胃肠或泌尿生殖毒性。
研究设计与样本
- PACE-B 为国际、3 期、开放标签、随机、非劣效性试验,在英国、爱尔兰和加拿大 37 个中心招募 874 例低危或中危前列腺腺癌男性(排除 Gleason 4+3),按 1:1 随机分配。
主要发现
- 未发生治疗相关死亡。
关键数值与推荐
- 不允许使用雄激素剥夺治疗。
临床怎么用
- 对于低危至中危局限性前列腺癌,可考虑使用 5 次 SBRT 缩短疗程,急性胃肠和泌尿生殖毒性未较常规分割或中度大分割放疗增加。
局限性
- 本研究仅报告 12 周内急性毒性,未涉及晚期毒性或生化/临床失败终点。
- 研究为开放标签设计,参与者和研究者均未设盲。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Localised prostate cancer is commonly treated with external-beam radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional fractionation. Ultra-hypofractionated stereotactic body radiotherapy would allow shorter treatment courses but could increase acute toxicity compared with conventionally fractionated or moderately hypofractionated radiotherapy. We report the acute toxicity findings from a randomised trial of standard-of-care conventionally fractionated or moderately hypofractionated radiotherapy versus five-fraction stereotactic body radiotherapy for low-risk to intermediate-risk localised prostate cancer. METHODS: PACE is an international, phase 3, open-label, randomised, non-inferiority trial. In PACE-B, eligible men aged 18 years and older, with WHO performance status 0-2, low-risk or intermediate-risk prostate adenocarcinoma (Gleason 4 + 3 excluded), and scheduled to receive radiotherapy were recruited from 37 centres in three countries (UK, Ireland, and Canada). Participants were randomly allocated (1:1) by computerised central randomisation with permuted blocks (size four and six), stratified by centre and risk group, to conventionally fractionated or moderately hypofractionated radiotherapy (78 Gy in 39 fractions over 7·8 weeks or 62 Gy in 20 fractions over 4 weeks, respectively) or stereotactic body radiotherapy (36·25 Gy in five fractions over 1-2 weeks). Neither participants nor investigators were masked to allocation. Androgen deprivation was not permitted. The primary endpoint of PACE-B is freedom from biochemical or clinical failure. The coprimary outcomes for this acute toxicity substudy were worst grade 2 or more severe Radiation Therapy Oncology Group (RTOG) gastrointestinal or genitourinary toxic effects score up to 12 weeks after radiotherapy. Analysis was per protocol. This study is registered with ClinicalTrials.gov, NCT01584258. PACE-B recruitment is complete and follow-up is ongoing. FINDINGS: Between Aug 7, 2012, and Jan 4, 2018, we randomly assigned 874 men to conventionally fractionated or moderately hypofractionated radiotherapy (n=441) or stereotactic body radiotherapy (n=433). 432 (98%) of 441 patients allocated to conventionally fractionated or moderately hypofractionated radiotherapy and 415 (96%) of 433 patients allocated to stereotactic body radiotherapy received at least one fraction of allocated treatment. Worst acute RTOG gastrointestinal toxic effect proportions were as follows: grade 2 or more severe toxic events in 53 (12%) of 432 patients in the conventionally fractionated or moderately hypofractionated radiotherapy group versus 43 (10%) of 415 patients in the stereotactic body radiotherapy group (difference -1·9 percentage points, 95% CI -6·2 to 2·4; p=0·38). Worst acute RTOG genitourinary toxicity proportions were as follows: grade 2 or worse toxicity in 118 (27%) of 432 patients in the conventionally fractionated or moderately hypofractionated radiotherapy group versus 96 (23%) of 415 patients in the stereotactic body radiotherapy group (difference -4·2 percentage points, 95% CI -10·0 to 1·7; p=0·16). No treatment-related deaths occurred. INTERPRETATION: Previous evidence (from the HYPO-RT-PC trial) suggested higher patient-reported toxicity with ultrahypofractionation. By contrast, our results suggest that substantially shortening treatment courses with stereotactic body radiotherapy does not increase either gastrointestinal or genitourinary acute toxicity. FUNDING: Accuray and National Institute of Health Research.
引用
- Brand DH, Tree AC, Ostler P, et al. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol. 2019. PMID: 31540791. doi:10.1016/S1470-2045(19)30569-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。